Metabolic Syndrome and Obesity in Peripheral Arterial Disease

Slides:



Advertisements
Similar presentations
Long-term Complications of Type 2 Diabetes
Advertisements

C-Reactive Protein: What Is It?  Marker of inflammation made in liver 1  Acute-phase response  Illness or injury 2  Adipocyte release of cytokines.
1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.
DO YOU HAVE THE METABOLIC SYNDROME? You're never too young to have it Jacqueline A. Eberstein, R.N.
Sex Differences in Overweight & Obesity.
Metabolic Syndrome Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference Circulation. 2004;109:
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
OBESITY and CHD Nathan Wong. OBESITY AHA and NIH have recognized obesity as a major modifiable risk factor for CHD Obesity is a risk factor for development.
Biochemical Markers in the inflammatory response Dr Claire Bethune Consultant Immunologist Derriford Hospital.
S_khalilzadeh. NAFLD and T2DM NAFLD is closely associated with features of the metabolic syndrome and is regarded as the hepatic manifestation of the.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Effects of Low-Fat Dairy Consumption on Markers of Low- Grade Systemic Inflammation and Endothelial Function in Overweight and Obese Subjects: An Intervention.
Obesity M.A.Kubtan MD - FRCS M.A.Kubtan1. 2  Pulmonary Disease  Fatty Liver Disease  Orthopedic Disorders  Gallbladder Disease  Psychological Impact.
Lower levels of ADAMTS13 are associated with cardiovascular disease by Supakanya Lasom Master Degree Student of Medical Sciences, Bongers T.N, Bruijne.
Chapter 5 Type 2 diabetes. Chapter overview Introduction Aetiology Prevalence Obesity as a risk factor Physical inactivity as a risk factor Low physical.
Amber Leon Jeanine Mills Erin Prasad Nutrition Assessment and Therapy 1 Winter 2012.
Inflammation and Course Themes Nancy Long Sieber, Ph.D. Sept. 12, 2011.
Early immune disorders induced by childhood obesity E Carolan, AH Hogan, D O’Shea.
By Hussam A.S. Murad and Khaled A. Mahmoud Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad.
Anthropometrics in Obesity Robert Kushner, MD Northwestern University Feinberg School of Medicine.
Physiological Role and Molecular Mechanism of Adiponectin Yumi Ando Pomona College Advanced Biochemistry.
Reem Sallam, MD, MSc. PhD Clinical Chemistry Unit, Pathology Dept. College of Medicine, King Saud University.
cardio protection: Focus on
Coagulation / Fibrinolytic Factors in PCOS. The Alternative Hypothesis : Conversely, PCOS women may be protected from later life onset of CHD by the altered.
Obesity & Inflammation: Relationships to Type 2 Diabetes and CVD Hannah Coakley January 10 th, 2014.
Towards better screening of CV risk Paul Ridker MD Associate Professor of Medicine Division of Preventive Medicine and Cardiovascular Diseases Harvard.
A.P.J. Houdijk Euro Weight Loss-2015 Frankfurt, Germany August 18 – 20, 2015.
The Relation of Interleukin 6 Gene-190 T/C Polymorphisms with Anthropometric and Biochemical Characteristics in a group of Obese Children Authors: Mărginean.
STEVIA SYMPOSIUM LEUVEN July 2009 EFFECT OF STEVIOSIDE ON ATHEROSCLEROSIS IN A MOUSE MODEL OF THE METABOLIC SYNDROME Paul Holvoet Atherosclerosis and Metabolism.
Plasminogen-Activating Inhibitor-1 (PAI-1) High PAI-1 associated with: Obesity (especially visceral), possible fatty liver. 2,3,4 Inflammation and oxidative.
Contemporary Management of Cardiometabolic Risk. A continuing epidemic: 2 of 3 US adults are overweight or obese National Health and Nutrition Examination.
The Road To Metabolic syndrome
Insulin Resistance Progression to Diabetes. Hypertension: BP >140/90 Dyslipidemia: ◦TG >150 mg/dL (1.7 mmol.L) ◦HDL-C
Inflammation and Course Themes Nancy Long Sieber, Ph.D. Sept. 14, 2009.
Distribution of metabolic syndrome (MS) components by age and gender Zhao D, et al. Am J Cardiol 2007;100:835– 839.
Controversial Pathophysiologic Contributors to Acute MI and Atherosclerosis Atherothrombotic events occur in individuals without readily apparent risk.
Vascular effects of PPAR  activation: Inflammation.
Insulin Resistance Progression to Diabetes Part 3.
Diabetes mellitus.
Vitamin D deficiency and anemia in early chronic kidney disease 2010/05/18 R4 이완수 2010.
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
 Insulin is a peptide hormone released by beta cells when glucose concentrations exceed normal levels (70–110 mg/dL).  The effects of insulin on its.
Source: International Chair on Cardiometabolic Risk Metabolic Syndrome and Adipose Tissue Yuji Matsuzawa, MD, PhD Director.
Abstract The metabolic syndrome (MetS) has surpassed smoking as the number one cause of cardiovascular deaths in the US. However, it remains under diagnosed.
Body Weight and Insulin Sensitivity Negative Correlation Insulin resistance may have evolved to prevent excessive weight gain BMI by CountyType II Diabetes.
Chapter 5 Type 2 diabetes.
AGEs and Complications
Cardiovascular Disease: Risk Factors and Risk Assessment
Plaque vulnerability Key role of macrophages
The role of unknown risk factors in coronary heart disease
NMR-Based Diabetes Risk Index is Capable of Identifying Normal Weight Subjects with High Likelihood of Progressing to Type 2 Diabetes Margery A. Connelly,
GLYPICAN-4 LEVELS IN RELATION WITH HORMONAL AND METABOLIC PROFILE IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME Doç.Dr.Özlem ALTINKAYA.
OBESITY.
Chapter 7 Metabolic syndrome
Elevated Circulating Levels of Inflammatory Markers in
ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH CRITERIA FOR THE CLINICAL DIAGNOSIS OF THE METABOLIC SYNDROME AS PROPOSED BY THE NCEP-ATP III Metabolic.
Intermyocellular fat depot
The percentage of subjects with de novo development of renal function impairment (GFR
Ischemic cardiovascular involvement in psoriasis: A systematic review
Clopidogrel Reduces ADP-Induced Expression of Platelet-derived CD40L
NAFLD, Obesity, and Bariatric Surgery
Ischemic cardiovascular involvement in psoriasis: A systematic review
Exercise and adult women’s health
Ludger Scheja, Joerg Heeren  Journal of Hepatology 
Nat. Rev. Cardiol. doi: /nrcardio
Hypothesised conceptual framework of the association between lung and vascular events. Hypothesised conceptual framework of the association between lung.
Figure 2 Mechanisms of crosstalk between adipocytes and the kidney
Section overview: Cardiometabolic risk reduction
Baseline Characteristics of Study Subjects
Ann Marie Schmidt, Kathryn J. Moore  Cell Metabolism 
Presentation transcript:

Metabolic Syndrome and Obesity in Peripheral Arterial Disease True Syndrome ? Mixture of unrelated phenotypes ? Fernando Botero, La famiglia

Metabolic Syndrome and Obesity in Peripheral Arterial Disease Syndrome is simply a clustering of factors that occur together more often than by chance alone and for which the cause is often uncertain. The metabolic syndrome fulfills these criteria Circulation october 20, 2009

Metabolic Syndrome and Obesity in Peripheral Arterial Disease Circulation october 20, 2009

Metabolic Syndrome and Obesity in Peripheral Arterial Disease Circulation october 20, 2009

Waist circumference correlates closely with visceral fat content Abdominal visceral fat area (cm2) Waist circumference correlates closely with visceral fat content Waist circumference (cm) Pouliot MC et al. Am J Cardiol 1994

Metabolic Syndrome and Obesity in Peripheral Arterial Disease Progression and outcomes of the metabolic syndrome. The metabolic syndrome arises largely out of abdominal obesity. With aging and increasing obesity, metabolic risk factors worsen. Many persons with the metabolic syndrome eventually develop type 2 diabetes. As the syndrome advances, risk for CV disease and its complications increase. Once diabetes develops, diabetic complications other than CV disease often develop. The metabolic syndrome encompasses each stage in the development of risk factors and type 2 diabetes. Grundy. JACC 2006

Metabolic Syndrome and Obesity in Peripheral Arterial Disease

Metabolic Syndrome and Obesity in Peripheral Arterial Disease: Inflammation and cytokines Pro-inflammatory cytokines including IL-1beta, IL-6, and tumor necrosis factor (TNF)-alpha are released from macrophages within the vessel wall during an inflammatory response. These cytokines mediate distant inflammatory effects, including activation of hepatic genes encoding acute phase reactants fibrinogen, CRP, and serum amyloid A. C-reactive protein induces synthesis of cytokines, CAMs, and tissue factor in monocytes and endothelial cells. Tissue factor activates the extrinsic coagulation cascade, providing a link between inflammation and thrombosis. Koh JACC 2005

Metabolic Syndrome and Obesity in Peripheral Arterial Disease: adiponectin Adiponectin is one of a number of proteins secreted by adipose cells that might couple regulation of insulin sensitivity with energy metabolism and serve to link obesity with insulin resistance. Adiponectin stimulates production of NO, reduces expression of adhesion molecules in endothelial cells, and decreases cytokine production. Plasma levels of adiponectin are negatively correlated with adiposity, and decreased plasma adiponectin levels are observed in patients with obesity and type II diabetes Koh JACC 2005

Metabolic Syndrome and Obesity in Peripheral Arterial Disease: link between inflammation and PAD McDermott JACC 2009

Metabolic Syndrome and Obesity in Peripheral Arterial Disease Patients with the metabolic syndrome are at twice the risk of developing CVD over the next 5 to 10 years as individuals without the syndrome. The risk over a lifetime undoubtedly is even higher. Furthermore, the metabolic syndrome confers a 5-fold increase in risk for type 2 diabetes mellitus. Conversely, little is known about the predictive role of MetS in peripheral arterial disease (PAD)

Metabolic Syndrome and Obesity in Peripheral Arterial Disease Much less information is available on the relationship between MetS and peripheral artery disease (PAD), with most data deriving from cross-sectional reports A prospective evaluations suggested that MetS is a predictor of end-stage PAD (lower-extremity amputation or revascularization) but that this risk increase is largely attributable to the impact of diabetes alone. Another recent analysis did not find a significant association of MetS with incident PAD, although a strong and independent relationship between MetS and cerebrovascular disease was noted.

Metabolic Syndrome and Obesity in Peripheral Arterial Disease MetS is associated with an increased risk of future symptomatic PAD in women. This risk appears to be mediated largely by the effects of inflammation and endothelial activation. (Conen Circulation. 2009;120:1041-1047.) Women with MetS had a 62% increased risk of future PAD (hazard ratio 1.62, 95% confidence interval 1.10 to 2.38). After multivariable adjustment, MetS remained significantly associated with PAD (adjusted hazard ratio 1.48, 95% confidence interval 1.01 to 2.18), with a 21% risk increase per additional MetS-defining trait (adjusted hazard ratio 1.21, 95% confidence interval 1.06 to 1.39).

Metabolic Syndrome and Obesity in Peripheral Arterial Disease Conen D et al. Circulation online Sept 2009

Metabolic Syndrome and Obesity in Peripheral Arterial Disease The metabolic syndrome is associated with a 1.5-fold increase in risk of vascular events in PAOD patients. Weight control reduces metabolic syndrome incidence and increases metabolic syndrome resolution during follow-up. (Vleck ALM J Vasc Surg 2009;50:61-9) The study population consisted of 461 patients with symptomatic PAOD Federation (IDF). The MetS was associated with an increased risk of vascular events (HR 1.51; 1.01-2.30, age- and gender-adjusted).

Metabolic Syndrome and Obesity in Peripheral Arterial Disease Vleck.Vasc Surg 2009

Metabolic Syndrome and Obesity in Peripheral Arterial Disease The degree of peripheral arterial disease clinical manifestations was not related to metabolic syndrome score, but gangrene was significantly positively associated with increased fasting glucose, high-sensitivity C-reactive protein, and lower education. (Maksimovic. Angiology 2009; 60; 546) This cross-sectional study involved 388 consecutive patients with verified PAD. Metabolic syndrome was present in 59.8% of the patients with peripheral arterial disease.

Metabolic Syndrome and Obesity in Peripheral Arterial Disease: Maksimovic. Angiology 2009

Metabolic Syndrome and Obesity in Peripheral Arterial Disease IDF-MEtS, but not rATP III-MetS, is an independent predictor of cardiovascular events. IDF-MEtS combined with an ABI<0.73 identifies a subgroup of claudicants at very high risk (Brevetti Nutrition, Metabolism & Cardiovascular Diseases 2009 ) 173 patients with intermittent claudication and ABI <0.90, in whom MetS was defined using the criteria of both Adults Treatment Panel III (rATP III) and International Diabetes Federation (IDF). IDF-MetS was independently associated with increased cardiovascular risk (HR 1.91, 95% CI 1.03-3.51, p=0.038).

Metabolic Syndrome and Obesity in Peripheral Arterial Disease Brevetti Nutr Metabol 2009

Metabolic Syndrome and Obesity in Peripheral Arterial Disease In conclusion, similar to the previously noted relationship between MetS and incident coronary heart disease and stroke, several studies suggest a positive association with PAD. Increased plasma levels of inflammatory markers were evident in subjects with MetS, and a strong influence of these factors on the relationship between MetS and PAD was noted, suggesting a possible pathophysiological role. Prospective data from cohorts are greatly needed not only to corroborate the actual results but also to further elucidate mechanistic links between risk factor clustering and onset of this disease..

Linee Guida Prevenzione Cardiovascolare Fernando Botero, La coppia

Metabolic Syndrome and Obesity in Peripheral Arterial Disease Mattioli AV ESC 2009

Metabolic Syndrome and Obesity in Peripheral Arterial Disease Mc Dermott JACC 2009